As learning and observations come out of clinical trails, should the parameters and guidelines change based on the evidence emerging? Yes - and clinical research organizations are starting to see the value in being flexible about changing dosage and patient populations according to statistically significant data coming out of trials. The industry is currently seeing the biggest impact in Phase II and Phase III clinical trials. However, changing dosing options often proves to be more difficult. What makes these trials possible is the electronic data capture of clinical data, and soon the two will be seamless making adaptive clinical trials a main-stay in the industry. Not only that, but this process is expected to save companies millions of dollars because they'll be able to see the data and terminate studies that are obviously not working and move that money to other compounds. Read more at Outsourcing Pharma.
Are you ready to discuss the pros and cons of the adaptive clinical trial process with your industry peers? What has and hasn't worked in adaptive clinical trials? This fall at the Clinical Collaboration Congress, we're bringing the industry together in the Adaptive Design Approaches to Advance Trial Design think tank on Friday, September 27. For more information on this session and the rest of the program, download the agenda. If you'd like to join us in Boston, as a reader of this blog when you register to join us and mention code XP1825BLOG, you'll save 15% off the standard rate.
What are the benefits you see in adaptive clinical trials?
The Partnerships in Clinical Trials Blog focuses on optimization intelligence, regulatory trends and globalization strategies for both sponsors and CROs. It is supported by a number of industry events.
Would you like to guest blog on our site? Or send us feedback? Send an email to email@example.com.